Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 39.70
Ask: 40.50
Change: 1.70 (4.38%)
Spread: 0.80 (2.015%)
Open: 39.60
High: 40.50
Low: 39.00
Prev. Close: 38.80
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Futura Announces Collaboration with Labatec Pharma

27 Sep 2021 07:00

RNS Number : 9779M
Futura Medical PLC
27 September 2021
 

 

 

 

27 September 2021

 

Futura Medical Announces Collaboration with Labatec Pharma to Commercialise MED3000 in the Gulf and Middle East Region

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with Labatec Pharma ("Labatec"), a Swiss-based specialty pharma Company focused on commercialisation in Europe and the Middle East and North Africa ("MENA") regions, for the rights to exclusively commercialise the Company's topical, gel-based Erectile Dysfunction ("ED") treatment MED3000, in the Gulf Co-operation Council ("GCC") region as well as Jordan, Lebanon and Iraq.

 

Commercial Highlights:

Futura eligible to receive initial upfront payments, as well as undisclosed milestone payments based on regulatory approvalLabatec to pay an agreed price to Futura for the manufacture and supply of MED3000 by Futura's Contract Manufacturing Organisation ("CMO"), plus royalties on all salesLabatec is responsible for all local MED3000 development and regulatory costs in GCC and Levant as well as all launch and marketing expensesInitial licence agreement term of 8 years with the ability to extend for successive two-year terms by mutual consent

 

Based in Switzerland and privately-owned, Labatec is a pharmaceutical company with a successful track record of delivering high quality pharmaceutical products to European and MENA markets. Labatec has a presence in both hospital and retail sectors, with prescription and OTC ranges and delivers a trusted brand of medicines manufactured in Europe and Canada.

 

Labatec Licensing Agreement

Under the terms of the agreement, which is for an initial 8-year period, Futura and Labatec will work together to gain marketing authorisation and commercialise MED3000 as a clinically proven treatment for ED in Jordan, Lebanon, Iraq and the GCC region of Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

 

Labatec will be responsible for all costs related to the regulatory approval and marketing of the product in the region. Labatec and Futura believe the EU (inclusive of the UK) approval of MED3000 will facilitate approval in GCC and other countries within the Middle East without the need for further clinical development. Futura will provide reasonable technical support for product development and commercialisation, will receive upfront and milestone payments, manufactured product from Futura's CMO and a royalty rate on all sales.

 

James Barder, Chief Executive of Futura Medical commented: "This is our third commercial agreement for MED3000, and we are excited to be working with Labatec to expand the product's market reach into Middle Eastern countries as we continue MED3000's regulatory and commercial rollout worldwide. Labatec is a trusted medicines supplier in the region that is ideally placed to market both prescription and retail products, and its local teams have deep understanding of regional markets and experience in rapidly registering and launching new products. We look forward to working closely with them."

 

Faisal Darwazeh, Chief Executive Officer of Labatec commented: "We are delighted to license Futura's MED3000 for the GCC and other Middle Eastern countries. We feel that there is significant market potential in the region for MED3000 as a trusted, branded medicine for enhancing erectile performance, optimally through pharmacy sales and are confident of generating significant value and long term sustainable growth for both Futura and Labatec with this innovative, clinically proven product."

 

Commercial Transaction Advisors

JSB Partners served as an adviser to Futura Medical in this transaction

www.jsb-partners.com

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com 

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 922 0900

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk. 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

 

About Labatec

A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva) since 1957, Labatec develops and markets medicines that contribute to improving patients' quality of life. Our portfolio includes more than 85 high quality products, manufactured in Europe and Canada and marketed in 10+ countries across MENA markets, Switzerland and neighbouring EU countries. Labatec is a recognised partner choice for Swiss and MENA hospitals and has an established retail presence, including an OTC range, in the therapeutic categories of musculo-skeletal, urology, and reproductive health. www.labatecpharma.com

 

In case Labatec contacts are needed:

Viktoria Stepanova, COO

Email: bd@labatec.com

Tel: +41 22 785 95 00 (Head Office)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPURCBUPGGPA
Date   Source Headline
25th Mar 20247:00 amRNSNotice of Results and Investor Presentation
14th Feb 20247:00 amRNSEroxon to be available on prescription
6th Feb 20247:01 amRNSTrading Update
6th Feb 20247:00 amRNSAppointment of Joint Corporate Broker
17th Jan 20247:00 amRNSDirector/PDMR Dealing
17th Jan 20247:00 amRNSRemuneration of Non-Exec Directors & Voting Rights
15th Jan 20247:00 amRNSFutura Medical extends collaboration with Cooper
9th Jan 20247:00 amRNSAppointment of Roy Davis as Non-Executive Director
30th Nov 20233:10 pmRNSTotal Voting Rights
30th Nov 20233:10 pmRNSBlock Listing Six Monthly Return
7th Nov 20237:00 amRNSFutura expands partnership with M8 Pharmaceuticals
2nd Nov 20233:34 pmRNSEroxon Awarded “New Product of the Year” by Boots
31st Oct 20237:00 amRNSBlock Listing Application and Total Voting Rights
25th Oct 20237:00 amRNSEroxon® Granted Marketing Authorisation in Mexico
19th Oct 20237:00 amRNSEroxon Launches in the United Arab Emirates
10th Oct 20237:00 amRNSDirectors’/PDMR Dealing and Grant of Options
2nd Oct 20237:00 amRNSEuropean Patent Granted for MED3000 until 2040
18th Sep 20237:00 amRNSFutura Medical - Interim Results 2023
18th Aug 20237:00 amRNSFutura Medical - Notice of Interim Results
31st Jul 20237:00 amRNSFutura Medical - Total Voting Rights
18th Jul 202311:04 amRNSBoard Change
17th Jul 20237:00 amRNSFutura/Haleon Enter US Commercialisation Agreement
30th Jun 20237:00 amRNSFutura Medical - Total Voting Rights
23rd Jun 20234:30 pmRNSRecording of Investor Seminar
22nd Jun 20233:19 pmRNSFutura Medical Annual General Meeting Results
22nd Jun 20237:00 amRNSFutura Medical AGM Statement
19th Jun 202310:25 amRNSCorrection - TR-1: Notification of major holdings
16th Jun 20234:05 pmRNSTR-1: Notification of major holdings
12th Jun 20238:23 amRNSExercise of Warrants
12th Jun 20237:00 amRNSMED3000 Granted US FDA Approval for OTC Sale
8th Jun 20237:00 amRNSFutura Medical Announces Investor Seminar
31st May 20237:00 amRNSBlock Listing Six Monthly Return
26th May 20237:00 amRNSNotice of AGM and availability of Annual Report
24th Apr 20237:00 amRNSTR-1: Notification of major holdings
18th Apr 20237:00 amRNSMED3000, Eroxon® UK Launch
6th Apr 202311:03 amRNSDirectors' / PDMR Dealing and Grant of Options
5th Apr 20237:00 amRNSFull Year Results ended 31 December 2022
29th Mar 20237:00 amRNSUpdate on MED3000 regulatory approval in the US
27th Mar 20235:24 pmRNSNotice of Preliminary Results 2022
14th Mar 20238:33 amRNSMED3000 commercial and US regulatory update
15th Feb 20237:00 amRNSMED3000 FM71 Presentation at ESSM Congress 2023
1st Feb 20231:26 pmRNSBlock Listing Applications to AIM
26th Jan 20237:00 amRNSPre-launch of MED3000 ahead of H1 2023 launch
12th Jan 202311:09 amRNSFutura Remuneration, Options & Total Voting Rights
15th Dec 20223:01 pmRNSTR-1: Notification of major holdings
13th Dec 20221:10 pmEQSFutura Medical 'on track' for launch in H1 2023
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.